source
- Sellas’ Phase 3 REGAL AML Immunotherapy Study Delayed, Forecast to Miss Survival EndpointSellas Life Sciences Group’s experimental immunotherapy galinpepimut‑S (GPS) is being tested in a Phase 3 REGAL trial for patients with acute myeloid leukemia in a second remission. The study has b…
- Biopharma hiring surges in Massachusetts and California, with science/R&D and clinical roles leading demandBioSpace data shows that biopharma job postings on its site rose 17% between January and August 2026, signaling a broad increase in employment opportunities. Massachusetts and California dominate…